Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial
Primary result · Serum PCSK9 levelsResult — go to the resultDifference −276.0 95% CI −468.2 to −83.9Authors' conclusion
Glucocorticoid treatment was associated with increased PCSK9 levels after 24 weeks. When compared with the bDMARD treatments, these increases were more pronounced in rheumatoid factor, anticitrullinated protein antibody and antinuclear antibody-positive patients.
Study context
- Population
- Newly diagnosed RA patients starting MTX with GC, certolizumab pegol, abatacept or tocilizumab
- Participants
- 296 participants
- Comparison
- MTX with GC vs MTX with biological disease-modifying antirheumatic drug (bDMARD)
- Primary endpoint
- Difference in serum PCSK9 and LDL-cholesterol levels between GC and bDMARD treatments
- Follow-up
- 24 weeks
Methodological detailslinear regression models
- Linear regression models
Primary result
Serum PCSK9 levels
Difference
−276.0
95% CI −468.2 to −83.9
bDMARDvs Glucocorticoid
difference −276.0 (95% CI −468.2 to −83.9)
As reported in the abstract
Further findings
PCSK9 by autoantibody status (interaction) · 24 weeks
- Increases with GC vs bDMARD more pronounced in autoantibody-positive patients
Low-density lipoprotein (LDL) cholesterol · 24 weeks
- Increased in all treatments; pattern distinct from PCSK9
Original publication
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial. RMD Open. Published 5 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →